Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
暂无分享,去创建一个
B. Skikne | S. Kambhampati | G. Garcia-Manero | A. Tefferi | S. Gore | W. Edenfield | C. Cogle | T. Shi | B. Scott | K. Macbeth | E. Laille | J. Hetzer | G. Garcia‐Manero | Keshava Kumar | K. Kumar